Candoxatril is a neutral endopeptidase (NEP) inhibitor with therapeutic potential, exhibiting anti-inflammatory and anti-fibrotic effects via cGMP-dependent mechanisms; it increases urinary cGMP levels and reduces α-SMA deposition in the kidney cortex, suggesting utility in treating fibrotic and inflammatory conditions.